Shanghai Bocimed Pharmaceutical Co., Ltd. (Bocimed) was established in Shanghai Zhangjiang Pharma Valley in 2012. Having two internal R&D centers settled in Shanghai and Nanjing, and a subsidiary clinical company in Chengdu, Bocimed now established an efficient R&D team with about 200 staffs and possesses specialized R&D equipments worth more 40 million RMB. Our comprehensive R&D platform mainly focuses upon small molecule innovative drugs, modified innovative drugs, highly difficult pharmaceutical preparations, DMF&MAH and clinical research, committing to provide global pharmaceutical companies with extremely competitive drug and create international and frontier pharmaceutical R&D and innovative platform.
Bocimed has more than 100 product development technologies, focusing on various therapeutic areas including oncology, cardiovascular science, immunology, neurological and mental health. With well-established internal intellectual property system,we have 16 authorized and 47 pending approval patents up to now.